Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440898 | 1.00 | BRD4 (0.34) | BRD4CTSKEPHX2KMT2AKCNH2 | |
| SCHEMBL440897 | 1.00 | BRD4 (0.34) | BRD4CTSKEPHX2KMT2AKCNH2 | |
| SCHEMBL408864 | 0.86 | NOTUM (0.32) | EPHX2 | |
| SCHEMBL440255 | 0.84 | EPHX2 (0.30) | EPHX2 | |
| SCHEMBL440254 | 0.84 | EPHX2 (0.30) | EPHX2 | |
| SCHEMBL440256 | 0.84 | EPHX2 (0.30) | EPHX2 | |
| SCHEMBL441068 | 0.79 | PKM (0.37) | CTSKEPHX2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL407345 | 0.79 | PKM (0.37) | CTSKEPHX2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL14305170 | 0.79 | KDM4E (0.34) | BRD4KMT2AKCNH2 | |
| SCHEMBL407388 | 0.74 | EPHX2 (0.34) | CTSKEPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | BRD4 864/4885CTSK 3044/4885EPHX2 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.